- Home
- CERT vs INBX Comparison
CERT vs INBX Comparison
Compare CERT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CERT | INBX |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CERT | INBX |
|---|---|---|
| Price | $7.16 | $76.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $12.22 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 141.1K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 87.50 | ★ 649.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,838,000.00 | $200,000.00 |
| Revenue This Year | $8.29 | $563.00 |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $6.04 | $10.81 |
| 52 Week High | $15.38 | $94.57 |
Technical Indicators
Market Signals| Indicator | CERT | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 47.84 |
| Support Level | N/A | $72.13 |
| Resistance Level | $11.53 | $85.97 |
| Average True Range (ATR) | 0.39 | 5.15 |
| MACD | 0.10 | -0.62 |
| Stochastic Oscillator | 78.76 | 40.15 |
Price Performance
Historical ComparisonAbout CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.